Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone908-617-1309
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$96.43 million
Profitability
Miscellaneous
Employees290
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable
Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions
What is Melinta Therapeutics' stock symbol?
Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT."
When did Melinta Therapeutics' stock split? How did Melinta Therapeutics' stock split work?
Melinta Therapeutics shares reverse split before market open on Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 21st 2019. An investor that had 100 shares of Melinta Therapeutics stock prior to the reverse split would have 20 shares after the split.
How were Melinta Therapeutics' earnings last quarter?
Melinta Therapeutics Inc (NASDAQ:MLNT) issued its quarterly earnings results on Thursday, May, 9th. The biotechnology company reported ($2.34) earnings per share for the quarter, beating the Zacks' consensus estimate of ($2.72) by $0.38. The biotechnology company earned $14.08 million during the quarter, compared to analyst estimates of $16.83 million. Melinta Therapeutics had a negative return on equity of 61.13% and a negative net margin of 161.27%. View Melinta Therapeutics' Earnings History.
When is Melinta Therapeutics' next earnings date?
What price target have analysts set for MLNT?
6 Wall Street analysts have issued 12 month price targets for Melinta Therapeutics' stock. Their forecasts range from $5.00 to $70.00. On average, they anticipate Melinta Therapeutics' share price to reach $41.25 in the next year. This suggests a possible upside of 1,462.5% from the stock's current price. View Analyst Price Targets for Melinta Therapeutics.
What is the consensus analysts' recommendation for Melinta Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Melinta Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Melinta Therapeutics.
What are Wall Street analysts saying about Melinta Therapeutics stock?
Here are some recent quotes from research analysts about Melinta Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution in 1Q19, we reiterate our OW rating and 12-month price target of $15 for MLNT shares. We continue to believe that upward earnings revisions and multiple expansion, from the uptake of its drugs, will drive the stock higher." (5/9/2019)
- 2. According to Zacks Investment Research, "Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products that were developed internally or assumed under the 2017 acquisition of Cempra, Inc. This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Melinta is headquartered in New Haven, CT. " (2/27/2019)
Has Melinta Therapeutics been receiving favorable news coverage?
Media stories about MLNT stock have trended positive recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Melinta Therapeutics earned a news sentiment score of 2.3 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.
Are investors shorting Melinta Therapeutics?
Melinta Therapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totalling 2,182,412 shares, an increase of 37.2% from the March 29th total of 1,590,418 shares. Based on an average daily trading volume, of 828,626 shares, the short-interest ratio is currently 2.6 days. Currently, 30.8% of the company's shares are short sold. View Melinta Therapeutics' Current Options Chain.
Who are some of Melinta Therapeutics' key competitors?
Some companies that are related to Melinta Therapeutics include CytoDyn (CYDY), Humanigen (HGEN), Osmotica Pharmaceuticals (OSMT), Chembio Diagnostics (CEMI), Corvus Pharmaceuticals (CRVS), Fortress Biotech (FBIO), AgeX Therapeutics (AGE), Arbutus Biopharma (ABUS), Trevena (TRVN), Aquestive Therapeutics (AQST), Ocular Therapeutix (OCUL), Aptinyx (APTX), AVEO Pharmaceuticals (AVEO), Spring Bank Pharmaceuticals (SBPH) and Sierra Oncology (SRRA).
What other stocks do shareholders of Melinta Therapeutics own?
Who are Melinta Therapeutics' key executives?
Melinta Therapeutics' management team includes the folowing people:
- Dr. Erin M. Duffy, Chief Scientific Officer & Exec. VP (Age 51)
- Mr. John H. Johnson, CEO & Director (Age 61)
- Dr. Thomas A. Steitz, Co-Founder
- Dr. Peter B. Moore Ph.D., Co-Founder
- Dr. William L. Jorgensen, Co-Founder
Who are Melinta Therapeutics' major shareholders?
Melinta Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.08%), FMR LLC (3.66%), Dimensional Fund Advisors LP (1.32%), Renaissance Technologies LLC (1.09%), Isthmus Partners LLC (0.75%) and Northern Trust Corp (0.67%). Company insiders that own Melinta Therapeutics stock include David N Gill, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Institutional Ownership Trends for Melinta Therapeutics.
Which institutional investors are selling Melinta Therapeutics stock?
MLNT stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Renaissance Technologies LLC, Dimensional Fund Advisors LP, Northern Trust Corp, Boenning & Scattergood Inc., Charles Schwab Investment Management Inc. and Spark Investment Management LLC. View Insider Buying and Selling for Melinta Therapeutics.
Which institutional investors are buying Melinta Therapeutics stock?
MLNT stock was purchased by a variety of institutional investors in the last quarter, including Isthmus Partners LLC and Algert Global LLC. Company insiders that have bought Melinta Therapeutics stock in the last two years include David N Gill, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Insider Buying and Selling for Melinta Therapeutics.
How do I buy shares of Melinta Therapeutics?
Shares of MLNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Melinta Therapeutics' stock price today?
One share of MLNT stock can currently be purchased for approximately $2.64.
How big of a company is Melinta Therapeutics?
Melinta Therapeutics has a market capitalization of $31.10 million and generates $96.43 million in revenue each year. The biotechnology company earns $-157,190,000.00 in net income (profit) each year or ($17.72) on an earnings per share basis. Melinta Therapeutics employs 290 workers across the globe.
What is Melinta Therapeutics' official website?
How can I contact Melinta Therapeutics?
Melinta Therapeutics' mailing address is 44 WHIPPANY ROAD SUITE 280, MORRISTOWN NJ, 07960. The biotechnology company can be reached via phone at 908-617-1309 or via email at [email protected]
MarketBeat Community Rating for Melinta Therapeutics (NASDAQ MLNT)
MarketBeat's community ratings are surveys of what our community members think about Melinta Therapeutics and other stocks. Vote "Outperform" if you believe MLNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
